Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
EGFR and BRAF V600E mutations are both early driven and usually mutually exclusive. We report the case of a 59-year-old woman diagnosed with advanced lung adenocarcinoma harboring coexisting EGFR exon 18 G719A and BRAF V600E mutations. She experienced a long-term response to oral afatinib, with a progression-free survival rate of 33 months and an overall survival rate of 11 years. Lung adenocarcinoma with synchronous EGFR G719A and BRAF V600E mutations is rare and has not been previously reported. This case highlights the importance of an adequate response to afatinib and provides an optimal therapeutic option for such patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CAD.0000000000001159 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting melanoma resistance: Novel oxindole and non-oxindole-based benzimidazole derivatives as potent dual inhibitors of BRAF and ABL2 kinases.
Eur J Med Chem
August 2025
Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, 61519, Minia, Egypt.
Melanoma is one of the deadliest forms of cancer. The disease is incurable for many due to its aggressive, metastatic characteristics and its elevated resistance. Herein, we design and synthesize two series of target compounds oxindole-based (7a-h) and non-oxindole-based (8a-h) benzimidazole.
View Article and Find Full Text PDFThe intrinsic ability of cancer cells to evade death underpins tumorigenesis, progression, metastasis and the survival of drug-tolerant persister (DTP) cells. Herein, we discovered that when activated, the small GTPase ARF6 plays a central role in tumor survival by facilitating expression of the BRAF oncoprotein. Tumor-specific deletion caused a significant reduction in BRAF protein and MAPK signaling and prevented rapid tumor progression.
View Article and Find Full Text PDFCytologic atypia is predictive of increased risk of malignancy and BRAF mutations in thyroid follicular neoplasms (Bethesda category IV).
J Am Soc Cytopathol
July 2025
Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Introduction: Molecular testing on thyroid fine needle aspirations with indeterminate cytology is integral to patient management. The aim of this study was to investigate the risk of malignancy in nodules diagnosed as Bethesda category IV, follicular neoplasm (FN), with and without cytologic atypia.
Methods: A total of 186 thyroid fine needle aspirations classified as Bethesda category IV (FN) were identified, and were categorized as FN with cytologic atypia or without cytologic atypia.
Diagnostic Evaluation of Anaplastic Thyroid Carcinoma in Core Biopsy Specimens: Morphologic, Immunohistochemical, Molecular, and Therapeutic Considerations.
Endocr Pathol
September 2025
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.
Although a diagnosis of anaplastic thyroid carcinoma (ATC) can be rendered on fine needle aspiration (FNA), a core needle biopsy is often performed to provide sufficient material for immunohistochemical and molecular analysis. Rendering an ATC diagnosis on core biopsy can be challenging due to limited material. It is crucial that other diagnostic entities in the differential, such as poorly differentiated thyroid carcinoma, medullary thyroid carcinoma, lymphoma, metastases, and NUT carcinoma (among others), are considered and that immunohistochemistry (IHC) is employed judiciously to support the diagnosis.
View Article and Find Full Text PDFPersonalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics.
Expert Opin Biol Ther
September 2025
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Introduction: Metastatic colorectal cancer (mCRC) remains a leading cause of cancer mortality worldwide, with limited long-term survival despite therapeutic advances. The increasing understanding of its molecular heterogeneity has paved the way for precision medicine approaches aiming to optimize treatment efficacy and reduce unnecessary toxicity.
Areas Covered: This review provides an in-depth analysis of the current and emerging molecular targets in mCRC, including RAS, BRAF, HER2, and microsatellite instability.